7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T10740 | CDK8-IN-1 | CDK | |
CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM). | |||
T10739 | CDK8/19-IN-1 | CDK | |
CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9). | |||
T5405 | BI-1347 | CDK | |
BI-1347 is a potent, selective inhibitor of CDK8/cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model. | |||
T21678 | 3MB-PP1 | PLK | |
3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifi... | |||
T81137 | SNX7886 | PROTACs | |
SNX7886 is a potent PROTAC (proteolysis-targeting chimera) that effectively degrades CDK8 and CDK19, achieving 90% degradation of CDK8 and 80% degradation of CDK19 in 293 cells [1]. | |||
T61742 | CDK8-IN-11 | ||
CDK8-IN-11 is a potent and selective inhibitor of CDK8, demonstrating an IC50 of 46 nM, and effectively targets the WNT/β-catenin signaling pathway. This compound has potential applications in colon cancer research [1]. | |||
T74784 | LL-K8-22 | ||
LL-K8-22 is a potent, selective, and durable dual degrader of CDK8-cyclin C, demonstrating DC50 values of 2.52 and 2.64 μM, respectively. This compound effectively suppresses STAT1 Ser 727 phosphorylation and inhibits ca... |